CYBB and endothelial dysfunction: Mechanistically anchored interventions, α/β-adrenergic blockade and α1AMPK activation, attenuate oxidative stress, inflammation and endothelial dysfunction, supporting combined exposure reduction, lifestyle targeting and NGS-guided repurposing of adrenergic/AMPK-modulating therapies as well as NOX-2/FOXO/TGF-β-focused validation studies in preclinical and early clinical settings.